Top

Journal of Endocrinological Investigation

02-11-2024 | Osteoporosis | Review Free for a limited time

Romosozumab for the treatment of osteoporosis – a systematic review

Authors: V.-N. Mäkinen, A. S. Sølling, M. McClung, B. L. Langdahl

Published in: Journal of Endocrinological Investigation

Abstract

Introduction

Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption. This systematic review aims to assess the clinical efficacy and safety of romosozumab for treatment of primary and secondary osteoporosis.

Methods

A comprehensive literature search was conducted in October 2023 across multiple databases including Embase, PubMed and Cochrane Library. Randomized controlled trials (RCTs) and observational studies evaluating the impact of romosozumab on BMD, bone turnover markers (BTM), fracture outcomes, and its safety profile were included. Data extraction and quality assessment were performed independently by two reviewers in accordance with PRISMA guidelines.

Results

A total of 36 articles met the inclusion criteria. Romosozumab significantly increased BMD at the lumbar spine, total hip, and femoral neck compared to placebo and active comparators in patients with primary osteoporosis. Sequential therapy with romosozumab followed by antiresorptives maintained or further increased BMD and reduced fracture risk. Romosozumab was generally well tolerated, however, an imbalance in cardiovascular adverse event was observed in one large clinical trial. Observational studies supported these findings. Specific subgroups of patients with secondary osteoporosis were assessed, demonstrating overall positive outcomes with romosozumab treatment.

Conclusion

Romosozumab effectively increases BMD and reduces fracture risk, particularly when used as initial therapy in high fracture-risk patients. Sequential therapy with subsequent antiresorptive treatment optimizes long-term benefits. While generally well-tolerated, its cardiovascular safety profile requires further long-term studies to ensure its safety in clinical practice. Additional studies are needed to confirm efficacy and safety in patients with secondary osteoporosis.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S et al (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577–589PubMedPubMedCentralCrossRef

Sølling ASK, Harsløf T, Langdahl B (2018) The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskel Dis 10(5–6):105–115CrossRef

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595–1622PubMedCrossRef

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71PubMedPubMedCentralCrossRef

Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26PubMedCrossRef

Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C et al (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54(2):168–178PubMedCrossRef

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420PubMedCrossRef

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181–187PubMedCrossRef

10.

Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B et al (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32(9):1956–1962PubMedCrossRef

11.

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397–1406PubMedCrossRef

12.

McClung M, Chines A, Brown J, Diez-Perez A, Resch H, Caminis J, et al (2014) Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J Bone Mineral Res Wiley-Blackwell 111 river ST, hoboken 07030–5774, NJ USA

13.

Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30(12):2437–2448PubMedPubMedCentralCrossRef

14.

Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M et al (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209–215PubMedCrossRef

15.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543PubMedCrossRef

16.

Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C et al (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33(8):1407–1416PubMedCrossRef

17.

Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34(3):419–428PubMedCrossRef

18.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427PubMedCrossRef

19.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, Phase 3 trial. The Lancet 390(10102):1585–1594CrossRef

20.

Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23(10):1591–1600PubMedCrossRef

21.

Hartz MC, Johannessen FB, Harsløf T, Langdahl BL (2024) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgae484CrossRefPubMed

22.

Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK et al (2021) Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metabol (Seoul, Korea) 36(1):60–69CrossRef

23.

Inage K, Orita S, Eguchi Y, Shiga Y, Koda M, Aoki Y et al (2021) Time-course changes in bone metabolism markers and density in patients with osteoporosis treated with romosozumab: a multicenter retrospective study. Yonsei Med J 62(9):829–835PubMedPubMedCentralCrossRef

24.

Hong N, Shin S, Lee S, Rhee Y (2023) Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int. https://doi.org/10.1007/s00198-023-06889-2CrossRefPubMed

25.

Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S et al (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574PubMedCrossRef

26.

Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219PubMedCrossRef

27.

Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J et al (2014) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep. https://doi.org/10.1016/j.bonr.2021.101068CrossRef

28.

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Scient Rep. https://doi.org/10.1038/s41598-021-91248-6CrossRef

29.

Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34(3):563–572PubMedCrossRef

30.

Inose H, Ariga A, Motoyoshi T, Fukushima K, Tomizawa S, Kato T et al (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study. JBMR Plus. https://doi.org/10.1002/jbm4.10637CrossRefPubMedPubMedCentral

31.

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32(10):1999–2009PubMedPubMedCentralCrossRef

32.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD et al (2018) A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183–3193PubMedCrossRef

33.

Miller PD (2014) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64(2):290–304PubMedCrossRef

34.

Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13(6):962–969PubMedPubMedCentralCrossRef

35.

Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39(6):1082–1090PubMedCrossRef

36.

Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N et al (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112(1):34–44PubMedCrossRef

37.

Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437–1445PubMedCrossRef

38.

Hsu CP, Maddox J, Block G, Bartley Y, Yu Z (2022) Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol 62(9):1132–1141PubMedPubMedCentralCrossRef

39.

Canalis E, Delany AM (2002) Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 966:73–81PubMedCrossRef

40.

Gado M, Baschant U, Hofbauer LC, Henneicke H (2022) Bad to the bone: the effects of therapeutic glucocorticoids on osteoblasts and osteocytes. Front Endocrinol (Lausanne) 13:835720PubMedCrossRef

41.

Thiele S, Hannemann A, Winzer M, Baschant U, Weidner H, Nauck M et al (2019) Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocr Connect 8(7):923–934PubMedPubMedCentralCrossRef

42.

Fassio A, Adami G, Giollo A, Viapiana O, Malavolta N, Saviola G et al (2020) Acute effects of glucocorticoid treatment, tnfα or il-6r blockade on bone turnover markers and wnt inhibitors in early rheumatoid arthritis: a pilot study. Calcif Tissue Int 106(4):371–377PubMedCrossRef

43.

Mochizuki T, Yano K, Ikari K, Okazaki K (2021) Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: an open-label, randomized, pilot study. Osteoporos Sarcopenia 7(3):110–114PubMedPubMedCentralCrossRef

44.

Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod Rheumatol 33(3):490–495PubMedCrossRef

45.

Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T et al (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33(1):96–103PubMedCrossRef

46.

Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW et al (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am Vol 102(8):693–702CrossRef

47.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M et al (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012–1021PubMedCrossRef

48.

Bhandari M, Schemitsch EH, Karachalios T, Sancheti P, Poolman RW, Caminis J et al (2020) Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture a randomized phase-2 study. J Bone Joint Surg 102(16):1416–1426PubMedCrossRef

49.

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American Association of Clinical endocrinologists/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1–46PubMedCrossRef

50.

McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J et al (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31(11):2231–2241PubMedPubMedCentralCrossRef

51.

Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J et al (2016) Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol 81:212–222PubMedCrossRef

52.

Inose H, Kato T, Tomizawa S, Ariga A, Motoyoshi T, Fukushima K et al (2022) Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: a multicenter retrospective study. Bone Rep 17:101635PubMedPubMedCentralCrossRef

53.

Langdahl BL, Hofbauer LC, Forfar JC (2021) Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 106(7):1845–1853PubMedCrossRef

54.

Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J et al (2016) WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res 345(2):206–217PubMedCrossRef

55.

Kocełak P, Puzianowska-Kuźnicka M, Olszanecka-Glinianowicz M, Chudek J (2024) Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification. Adv Clin Exp Med 33(5):519–532PubMedCrossRef

56.

Li M, Zhou H, Yang M, Xing C (2019) Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol 51(2):311–323PubMedCrossRef

57.

Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56(1):42–47PubMedCrossRef

58.

Burger F, Roth A, Mach F, Thouverey C, Ferrari SL, Miteva K (2024) Reduced sclerostin expression in human atherosclerotic plaques links to ischemic stroke. J Am Heart Assoc 13(10):e033038PubMedPubMedCentralCrossRef

59.

Amgen I. Background Information for Bone, Reproductive and Urologic Drugs Advisory Committee https://public4.pagefreezer.com/browse/FDA/04-03-2022T19:30/https://www.fda.gov/media/121255/download2019

60.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809PubMedCrossRef

61.

Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT et al (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33(8):1422–1434PubMedCrossRef

62.

Rodríguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP et al (2020) Oral bisphosphonate use reduces cardiovascular events in a cohort of danish patients referred for bone mineral density. J Clin Endocrinol Metab. 105(10):3215–3225CrossRef

63.

Casula M, Olmastroni E, Galimberti F, Tragni E, Corrao G, Scotti L et al (2020) Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: a population-based study. Atherosclerosis 301:1–7PubMedCrossRef

64.

Cummings SR, McCulloch C (2020) Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int 31(6):1019–1021PubMedCrossRef

65.

Turk JR, Deaton AM, Yin J, Stolina M, Felx M, Boyd G et al (2020) Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol 115:104697PubMedCrossRef

66.

van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE (2017) Sclerostin deficiency in humans. Bone 96:51–62PubMedCrossRef

67.

Lv F, Cai X, Yang W, Gao L, Chen L, Wu J et al (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone 130:115121PubMedCrossRef

68.

Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC, Ferreira T et al (2020) Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aay6570CrossRefPubMedPubMedCentral

69.

Holdsworth G, Staley JR, Hall P, van Koeverden I, Vangjeli C, Okoye R et al (2021) Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans. J Bone Miner Res 36(7):1326–1339PubMedCrossRef

70.

Takeuchi Y (2021) Romosozumab and cardiovascular safety in Japan. Osteoporos Sarcopenia 7(3):89–91PubMedPubMedCentralCrossRef

71.

Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the us Food and DRUG ADministration Adverse Event Reporting System (FAERS). J Clin Med. 10(8):1660PubMedPubMedCentralCrossRef

72.

Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H et al (2015) Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One 10(5):e0126413PubMedPubMedCentralCrossRef

73.

Lewiecki EM, Cummings SR, Cosman F (2013) Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 98(3):946–953PubMedCrossRef

74.

Thomas T, Casado E, Geusens P, Lems WF, Timoshanko J, Taylor D et al (2020) Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts. Osteoporos Int 31(12):2303–2311PubMedPubMedCentralCrossRef

75.

Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract. https://doi.org/10.1016/j.eprac.2024.01.014CrossRefPubMed

76.

Cosman F, Lewiecki EM, Eastell R, Ebeling PR, De Beur SJ, Langdahl B et al (2024) Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. J Bone Miner Res. https://doi.org/10.1093/jbmr/zjae119CrossRefPubMedPubMedCentral

77.

El Miedany Y, Bahlas S (2022) Treat-to-Target in Osteoporosis. In: El Miedany Y (ed) New Horizons in Osteoporosis Management. Springer International Publishing, Cham, pp 473–489CrossRef

78.

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32(10):1951–1960PubMedCrossRef

79.

Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1–12PubMedCrossRef

Title: Romosozumab for the treatment of osteoporosis – a systematic review
Authors: V.-N. Mäkinen
A. S. Sølling
M. McClung
B. L. Langdahl
Publication date: 02-11-2024
Publisher: Springer International Publishing
Keywords: Osteoporosis
Drug Therapy in Internal Medicine
Post-Menopausal Osteoporosis
Endocrinology
Published in: Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02469-1

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine